Meg Tirrell joined CNBC in April 2014 as a general assignment reporter focusing on biotechnology and pharmaceuticals. She appears on CNBC's Business Day programming, contributes to CNBC.com and is based at the network's global headquarters in Englewood Cliffs, N.J.
Tirrell has covered development of new drugs for Alzheimer's, cancer and rare diseases, and tracked public health emergencies from Ebola to Zika. Her work has explored why fewer drugs are developed for children, chronicled the sequencing of her own genome, and followed the manufacturing of a flu shot from egg to pharmacy. In 2014, she revealed the agonizing decision-making behind Compassionate Use of unapproved drugs, and in 2016, she reported extensively on drug pricing controversies and the impact of politics on development of new medicines.
Prior to joining CNBC, Tirrell covered the biotechnology industry for Bloomberg News, where she also contributed to Bloomberg Television and Bloomberg Businessweek.
She holds a master's degree in journalism from Northwestern University and a bachelor's degree in English and music from Wellesley College.
Follow her on Twitter @megtirrell.
Mosquitos are the deadliest of all creatures, so scientists are trying a new idea: Creating even more deadly mosquitos to fight back.
CNBC's Meg Tirrell discusses Google's efforts to stop the Zika virus.
CNBC's Meg Tirrell takes a look at the efforts from those like Google to combat the threats from mosquito-borne viruses.
CNBC's Meg Tirrell reports on efforts to battle mosquito-related diseases, like Zika, in new trials being tested in Key West, Florida.
CNBC's Meg Tirrell reports Vertex's drug trials for cystic fibrosis were better than the Street expected.
Vertex is attempting to expand treatment options to about 40 percent of cystic fibrosis patients.
CNBC's Meg Tirrell reports that Vertex's cystic firbrosis drugs improve lung function and shares are popping after hours.
CNBC's Meg Tirrell reports on Vertex reporting results from its 3-drug cystic fibrosis combinations.
CNBC's Meg Tirrell reports on a jump in shares of Puma after the FDA approves a drug for breast cancer and the projected costs of the drug.